Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05602727
Registration number
NCT05602727
Ethics application status
Date submitted
27/10/2022
Date registered
2/11/2022
Titles & IDs
Public title
Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)
Query!
Scientific title
A Phase 2a/2b Randomized, Placebo-Controlled Clinical Study To Evaluate The Safety And Efficacy Of MK-1942 As Adjunctive Therapy In Participants With Mild To Moderate Alzheimer's Disease Dementia
Query!
Secondary ID [1]
0
0
MK-1942-008
Query!
Secondary ID [2]
0
0
1942-008
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Alzheimer's Disease
0
0
Query!
Condition category
Condition code
Neurological
0
0
0
0
Query!
Alzheimer's disease
Query!
Neurological
0
0
0
0
Query!
Dementias
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - MK-1942
Treatment: Drugs - Placebo
Experimental: MK-1942 5 mg - Participants will receive a single 5 mg MK-1942 capsule twice daily (BID), taken orally for 12 weeks. A mock titration will be done to maintain the study blind despite no changes in dose.
Experimental: MK-1942 15 mg - Participants will receive a single 8 mg MK-1942 capsule twice daily (BID), taken orally for one week. Then the dose is titrated up to 15 mg MK-1942 capsule twice daily (BID), taken orally for up to 11 weeks.
Placebo comparator: Placebo - Participants will receive a placebo capsule twice daily (BID), taken orally for 12 weeks. A mock titration will be done to maintain the study blind despite no changes in dose.
Treatment: Drugs: MK-1942
MK-1942 oral capsule
Treatment: Drugs: Placebo
Placebo oral capsule
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Mean Change From Baseline in the Alzheimer's Disease Assessment Scale-11-item Cognitive Subscale (ADAS-Cog11) Score at Week 12
Query!
Assessment method [1]
0
0
Mean change from baseline at week 12 is assessed for ADAS-Cog11 score. The ADAS-Cog11 is a structured scale that evaluates memory, orientation, attention, reasoning, language, and constructional praxis. ADAS-Cog11 measures cognition by assessing 11 metrics impaired in AD: word recall; commands; constructional praxis; naming objects and fingers; ideational praxis; orientation; word recognition; remembering test instructions; spoken language ability; word-finding difficulty; and comprehension of spoken language. Higher scores indicate greater impairment.
Query!
Timepoint [1]
0
0
Baseline and Week 12
Query!
Primary outcome [2]
0
0
Number of Participants Experiencing an Adverse Event (AE)
Query!
Assessment method [2]
0
0
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Query!
Timepoint [2]
0
0
Up to ~ 14 Weeks
Query!
Primary outcome [3]
0
0
Number of Participants Discontinuing Study Medication due to an Adverse Event
Query!
Assessment method [3]
0
0
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Query!
Timepoint [3]
0
0
Up to ~ 12 Weeks
Query!
Secondary outcome [1]
0
0
Alzheimer's Disease Cooperative Study Clinical Global Impression of Change (ADCS-CGIC) Overall Score at Week 12
Query!
Assessment method [1]
0
0
ADCS-CGIC scores are assessed at week 12. The ADCS-CGIC is a global scale assessing cognition and function based on structured interviews of both the participant and study partner. The ADCS-CGIC focuses on clinicians' observations of change in the patient's cognitive, functional, and behavioral performance since the beginning of the study. Improvement in the ADCS-CGIC overall score, with a score of 1, 2, or 3 indicates improvement. The ADCS-CGIC is a clinician-rated measure of: global severity at baseline scored from 1 (normal, not at all ill) to 7 (among the most extremely ill patients); and global change at follow-up scored from 1 (marked improvement) to 7 (marked worsening), where 4 indicates no change.
Query!
Timepoint [1]
0
0
Week 12
Query!
Secondary outcome [2]
0
0
Mean Change From Baseline in The Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Total Score at Week 12
Query!
Assessment method [2]
0
0
Mean change from baseline at week 12 is assessed for ADCS-ADL score. The ADCS-ADL is an informant-based measure of the patient's functional ability in activities of daily living (ADL). The ADCS-ADL assesses the competence of participants with AD dementia in basic and instrumental ADLs. The ADCS-ADL is a 23 item scale that includes 6 basic ADL tems and 17 instrumental ADL items that provide a total score from 0-78, with a lower score indicating greater severity.
Query!
Timepoint [2]
0
0
Baseline and Week 12
Query!
Eligibility
Key inclusion criteria
* Has mild to moderate AD dementia based on the national institute of neurological and communicative diseases and stroke/Alzheimer's Disease and related disorders association (NINCDS-ADRDA) criteria.
* Has mini-mental state examination (MMSE) score between 12-22 (inclusive) at screening.
* Is using acetylcholinesterase inhibitors (AChEI) therapy for management of AD dementia at Screening and during the study. These medications must be at stable approved dose levels =3 months before the first dose of study intervention and the regimens must remain constant throughout the study to the extent that is clinically appropriate.
* Has a designated study partner who can fulfill the requirements of this study. The study partner will need to spend sufficient time with the participant to be familiar with their overall function and behavior and be able to provide adequate information about the participant needed for the study including, knowledge of functional and basic activities of daily life, work/educational history, cognitive performance, emotional/psychological state, and general health status.
Query!
Minimum age
55
Years
Query!
Query!
Maximum age
90
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Has a known history of stroke or cerebrovascular disease that is clinically important in the investigator's opinion.
* Has diagnosis of a clinically relevant central nervous system (CNS) disease other than AD dementia (with protocol-specified exceptions).
* Has a history of seizures or epilepsy within the 10 years preceding Screening.
* Has any other major CNS trauma, or infections that affect brain function.
* Has evidence of a clinically relevant or unstable psychiatric disorder, based on criteria from the diagnostic and statistical manual of mental disorders (fifth edition), including schizophrenia or other psychotic disorder, bipolar disorder, major depression, or delirium. Major depression in remission is not exclusionary.
* Has a severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or administration intervention.
* Has a history of malignancy occurring within the 5 years immediately before Screening, except for a participant who has been adequately treated for 1 or more of the following: basal cell or squamous cell skin cancer; in situ cervical cancer; localized prostate carcinoma; who has undergone potentially curative therapy with no evidence of recurrence for =3 years post-therapy, and who is deemed to be at low risk for recurrence.
* Has a risk factor for QTc prolongation.
* Has a history of alcoholism or drug dependency/abuse within the 5 years preceding screening.
* Has a known allergy or intolerance to the active or inert ingredients in MK-1942.
* Has received any anti-amyloid agents or antibodies, or any of the following medications: CNS-penetrant anticholinergics, neuroleptics, anticonvulsants, narcotics, glutamatergic agents, agents with possible psychotropic effects, and experimental acute respiratory syndrome coronavirus 2 (COVID-19) therapies.
* Has liver disease, including but not limited to chronic viral hepatitis, non viral hepatitis, cirrhosis, malignancies, autoimmune liver diseases.
* Has an abnormal thyroid-stimulating hormone (TSH) value if confirmed by abnormal T4 value.
* Resides in a nursing home or assisted care facility with need for direct continuous medical care and nursing supervision. Participant may reside in such facilities provided continuous direct medical care is not required and a qualified study partner is available for coparticipation and the participant is physically able to attend all required study visits.
* Had major surgical procedure or donated or lost >1 unit of blood (approximately 500 mL) within the 4 weeks before screening.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
2/12/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
27/09/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
99
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
KARA Institute for Neurological Diseases ( Site 1902) - Sydney
Query!
Recruitment hospital [2]
0
0
Austin Health-Medical & Cognitive Research Unit ( Site 1901) - Ivanhoe
Query!
Recruitment hospital [3]
0
0
HammondCare ( Site 1903) - Malvern
Query!
Recruitment postcode(s) [1]
0
0
2113 - Sydney
Query!
Recruitment postcode(s) [2]
0
0
3079 - Ivanhoe
Query!
Recruitment postcode(s) [3]
0
0
3144 - Malvern
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Louisiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New Jersey
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New York
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
North Carolina
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Ohio
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Oregon
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Texas
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Vermont
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Virginia
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Washington
Query!
Country [16]
0
0
Argentina
Query!
State/province [16]
0
0
Buenos Aires
Query!
Country [17]
0
0
Argentina
Query!
State/province [17]
0
0
Caba
Query!
Country [18]
0
0
Argentina
Query!
State/province [18]
0
0
Cordoba
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
British Columbia
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Nova Scotia
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Ontario
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Quebec
Query!
Country [23]
0
0
Colombia
Query!
State/province [23]
0
0
Antioquia
Query!
Country [24]
0
0
Colombia
Query!
State/province [24]
0
0
Distrito Capital De Bogota
Query!
Country [25]
0
0
Colombia
Query!
State/province [25]
0
0
Valle Del Cauca
Query!
Country [26]
0
0
Italy
Query!
State/province [26]
0
0
Lazio
Query!
Country [27]
0
0
Italy
Query!
State/province [27]
0
0
Lombardia
Query!
Country [28]
0
0
Italy
Query!
State/province [28]
0
0
Brescia
Query!
Country [29]
0
0
Japan
Query!
State/province [29]
0
0
Hyogo
Query!
Country [30]
0
0
Japan
Query!
State/province [30]
0
0
Kagawa
Query!
Country [31]
0
0
Japan
Query!
State/province [31]
0
0
Kanagawa
Query!
Country [32]
0
0
Japan
Query!
State/province [32]
0
0
Osaka
Query!
Country [33]
0
0
Japan
Query!
State/province [33]
0
0
Tokyo
Query!
Country [34]
0
0
Japan
Query!
State/province [34]
0
0
Kyoto
Query!
Country [35]
0
0
Korea, Republic of
Query!
State/province [35]
0
0
Incheon
Query!
Country [36]
0
0
Korea, Republic of
Query!
State/province [36]
0
0
Seoul
Query!
Country [37]
0
0
New Zealand
Query!
State/province [37]
0
0
Canterbury
Query!
Country [38]
0
0
Spain
Query!
State/province [38]
0
0
Barcelona
Query!
Country [39]
0
0
Spain
Query!
State/province [39]
0
0
Cataluna
Query!
Country [40]
0
0
Spain
Query!
State/province [40]
0
0
Navarra
Query!
Country [41]
0
0
Spain
Query!
State/province [41]
0
0
Pais Vasco
Query!
Country [42]
0
0
Spain
Query!
State/province [42]
0
0
Valenciana, Comunitat
Query!
Country [43]
0
0
Spain
Query!
State/province [43]
0
0
Madrid
Query!
Country [44]
0
0
Spain
Query!
State/province [44]
0
0
Zaragoza
Query!
Country [45]
0
0
United Kingdom
Query!
State/province [45]
0
0
Edinburgh, City Of
Query!
Country [46]
0
0
United Kingdom
Query!
State/province [46]
0
0
Glasgow City
Query!
Country [47]
0
0
United Kingdom
Query!
State/province [47]
0
0
London, City Of
Query!
Country [48]
0
0
United Kingdom
Query!
State/province [48]
0
0
Wiltshire
Query!
Country [49]
0
0
United Kingdom
Query!
State/province [49]
0
0
Birmingham
Query!
Country [50]
0
0
United Kingdom
Query!
State/province [50]
0
0
Plymouth
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Merck Sharp & Dohme LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The main purpose of this study is to assess is to evaluate the safety and efficacy of MK-1942 as adjunctive therapy in participants with mild to moderate Alzheimer's Disease (AD) dementia.
Query!
Trial website
https://clinicaltrials.gov/study/NCT05602727
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director
Query!
Address
0
0
Merck Sharp & Dohme LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Query!
When will data be available (start and end dates)?
Query!
Available to whom?
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: http://engagezone.msd.com/ds_documentation.php
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT05602727